Abstract
In recent years, new treatment for renal cell carcinoma (RCC) has been a spotlight in the field of cancer therapeutics. With several emerging agents branded as 'targeted therapy' now available, both medical oncologists and urologists are progressively more hopeful for better outcomes. The new remedies may provide patients with improved survival and at the same time less toxicity when compared to traditional cytotoxic agents. This article will center on current and emerging treatment strategies for advanced RCC and other GU malignancies with updates from 2008 annual ASCO meeting.

Renal cell cancer
For many years the treatment of advanced RCC was limited to the immunotherapy with interleukin-2 (IL-2) and interferon-α (IFN-α). The advent of targeted agents beginning in late 2005 filled a prolonged void of relatively fruitless therapies. The approval of the tyrosine kinase inhibitor sorafenib in December, 2005 both opened the door for the entrance of numerous other agents that became readily available, and also gave new optimism to patients afflicted with RCC.

Traditionally, surgical resection of RCC was ultimately the only consistent curative option for patients with localized disease, but the efficacy of available treatments for widespread disease remained marginal at best. Historically, spontaneous remissions observed in patients with RCC were thought to be a product of an immune response; this became the foundation behind the development of immune therapy beginning in the early 1980's [5]. Cytokine therapy with IL-2 and IFN-α became widely accepted as the standard of care for patients with extensive disease. High dose bolus IL-2 can trigger an immune response against RCC, but it will achieve a response rate only between 10 to 20% in patients, and is associated with severe life-threatening toxicities [6]. Monotherapy with IFN-α heralded a more tolerable toxicity profile but also shared a limited response rate of less than 10% [7].

New biologic agents with promising anti-tumor properties and a more favorable toxicity profile stemmed from the study of patients with Von Hippel-Lindau (VHL) disease, a familial cancer syndrome [8]. A better understanding of the VHL tumor suppressor gene and its role in up-regulating growth factors associated with angiogenesis...
spawned a novel approach to treating RCC that was dramatically different from traditional therapies [9]. Growth factors such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and platelet-derived growth factor (PDGF) and their downstream signalling pathways including phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) became new targets in the crusade against RCC. Here we have concisely reviewed recent progress in the targeted treatment of RCC and summarized its results in Table 1.

**Tyrosine kinase inhibitors (TKI)**

**Sorafenib**

Sorafenib is a small molecule multi-kinase inhibitor with effects on tumor cell proliferation and tumor angiogenesis. It was initially developed as an inhibitor of Raf kinase, but also has broad spectrum activity against multiple tyrosine kinases including vascular endothelial growth factor receptor family (VEGFR 1, 2, 3), platelet-derived growth factor receptor family (PDGFR-β), stem cell growth factor receptor (c-KIT), Fms-like tyrosine kinase 3 (Flt-3), and the receptor encoded by the ret proto-oncogene (RET) [10]. Its efficacy for RCC was first shown in a phase II randomized discontinuation trial [11], and became the first drug approved for the treatment of advanced RCC since the approval of interleukin-2 in 1992. The median progression-free survival (PFS) was significantly longer in patients treated with sorafenib (24 weeks) than placebo (6 weeks). Based on these results, a randomized phase III trial was performed comparing sorafenib with placebo in patients with cytokine-refractory metastatic clear cell RCC. It demonstrated superiority of sorafenib which carried a median PFS of 5.5 months versus 2.8 months when compared to placebo [12]. The final analysis from this study revealed a median survival of 17.8 months in patients receiving sorafenib versus 15.2 months in patients receiving placebo. Although this was not statistically significant, further analysis showed a confounding effect of crossover from placebo to sorafenib [13].

Further studies are underway defining the role of sorafenib in the first-line setting. In a phase II randomized trial in patients with previously untreated advanced RCC, sorafenib was compared to IFN-α. There was no significant difference in PFS between sorafenib and IFN-α. A PFS benefit was observed in patients who crossed to sorafenib after progression on IFN-α. Patients who were dose escalated to 600 mg bid after disease progression had disease stabilization for a further 3.6 months [14]. These studies reinforced the rationale behind continuing large multicenter trials utilizing sorafenib in advanced RCC.

The role of sorafenib in RCC patients refractory to other anti-VGF therapy is not clear. In a multicenter prospective trial of sorafenib in patients with metastatic RCC refrac-

| Table 1: Indication and efficacy for selected agents in advanced RCC |
|---|
| **Indications** | **Agent** | **Target** | **Efficacy** |
| 1st line | | | |
| Poor risk | Temsirolimus | mTOR | Survival benefit (HR: 0.73) [33] |
| Good risk and clear cell | High dose IL-2 | Immunomodulation | ORR: 14% (potential durable response) [99,100] |
| Good and intermediate risk | Sunitinib | VEGFR 1,2,3, PDGFR α,β Abl, Src | Survival benefit (HR: 0.82) [22] |
| Good and intermediate risk | Bevacizumab/Interferon | VEGF/Immunomodulation | PFS benefit (HR: 0.63) [49] |

| 2nd line | | | |
| Prior cytokine therapy | Sorafenib | VEGFR 1,2,3, PDGFR, C-kit, Flt-3, RET | PFS benefit (HR: 0.44) [12] |
| Prior TKIs | Everolimus | mTOR | PFS benefit (HR: 0.30) [35] |

**Clinical trials**

| | | |
| Thalidomide | Immunomodulation and angiogenesis | ORR: 0% [42] |
| Lenalidomide | Immunomodulation and angiogenesis | ORR: 11% [44] |
| Axitinib | VEGFR 1,2, PDGFR, C-kit | ORR: 21–44.2% [24,101] |
| Pazopanib | VEGFR 1,2,3, PDGFR, C-kit | ORR: 34.7% [27] |
| Cediranib | VEGFR 1,2,3, PDGFR, C-kit, FLT-4 | ORR: 38% [29] |
| G250 | CA IX | ORR: 10% [57] |
| Ixabepilone | Cytotoxic | ORR: 12.6% [58] |

**Abbreviations:** RCC, renal cell cancer; mTOR, mammalian target of rapamycin; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet derived growth factor receptor; c-KIT, stem-cell growth factor receptor; Flt-3 and -4, Fms-like tyrosine kinases 3 and 4; HR, hazard ratio; ORR, objective response rate; PFS, progression-free survival.
Sorafenib-associated adverse effects, which are different from that of classical chemotherapy, include predominantly gastrointestinal and cutaneous manifestations with hand-foot skin reaction (HFSR) and diarrhea being the most common events. A recent meta-analysis of 11 randomized trials showed that among 4883 patients receiving sorafenib, the summary incidences of all-grade and high-grade HFSR were 33.8% and 8.9% respectively. Sorafenib was associated with a significantly increased risk of all-grade HFSR when compared with controls (RR: 6.6, 95% CI: 3.7 to 11.7, p < 0.001). Interestingly, the incidence of HFSR is significantly higher in patients with RCC than non-RCC malignancies (RR: 1.52, 95% CI: 1.32–1.75%, p < 0.001) [16].

**Sunitinib**

Similar to sorafenib, sunitinib is a small molecule inhibitor of multiple tyrosine kinases including VEGFR, PDGFR α and β, Src, Abl, insulin-like growth factor receptor-1, and fibroblast growth factor receptor-1 tyrosine kinase [17]. A phase I study revealed initial activity in RCC and gastrointestinal stromal tumors [18]. Two phase II studies established its potent activity in RCC. The initial study enrolled patients predominantly pretreated with immunotherapy, and showed a 40% objective response rate and a median time to progression of 8.7 months [19]. The following study shared similar results with a response rate of 34% and median progression-free survival of 8.3 months [20]. Toxicities reported from these trials were predominantly fatigue, nausea, diarrhea and stomatitis. A handful of patients was found to have a significant decrease in myocardial ejection fraction leading termination of drug administration [20].

The success of sunitinib in the treatment of cytokine-refractory RCC led the way for the phase III study in the first-line setting [21]. Seven hundred fifty previously untreated patients with RCC were randomized to sunitinib or IFN-α, and the survival results were recently updated at ASCO 2008 [22]. The objective response rate (ORR) was significantly increased with sunitinib (47%) when compared to IFN-α (12%). The median PFS was also significantly higher in the sunitinib group (11 months) when compared to the IFN-α group (5 months). Median overall survival (OS) was also greater in the sunitinib group (26.4 months) compared with the IFN-α group (21.8 months) with a hazard ration of 0.82 [22]. Quality of life was significantly better in the sunitinib group. This trial ultimately established sunitinib as the first-line therapy for advanced RCC.

Sunitinib is also being analyzed in the adjuvant setting. The ‘Sunitinib Treatment of Renal Adjuvant Cancer’ (S-TRAC) study is a randomized double blind placebo controlled trial examining RCC patients with locally advanced but not metastatic disease 10 weeks following radical nephrectomy. Patients will be treated with sunitinib or placebo for 1 year, and disease-free survival and OS will be among the endpoints evaluated [23]. Sunitinib is also being evaluated in combination with other agents in the treatment of advanced RCC.

**Axitinib**

Axitinib (AG013736) is an orally active multi-kinase inhibitor that inhibits the receptor tyrosine kinases VEGFR 1 and 2, PDGFR and c-KIT. In a phase II trial of 52 patients with advanced RCC, an ORR of 44.2% was observed with a similar safety profile as other tyrosine kinase inhibitors [24]. Another phase II study of 62 patients refractory to tyrosine kinase inhibitors showed promising results with 21% of patients achieving partial response and 34% achieving stable disease [25]. Results of a phase II multicenter trial using axitinib in patients with metastatic RCC refractory to cytokines and sorafenib, sorafenib and sunitinib, or sorafenib alone was presented at ASCO 2008 [26]. In patients refractory to sunitinib and sorafenib, the ORR was 7% and median PFS was 7.1 months; in patients refractory to cytokines and sorafenib, the ORR was 28% and median PFS was 9 months; in patients refractory to sorafenib alone, the ORR was 27% and the median PFS was 7.7 months. It was concluded that axitinib has anti-tumor activity in patients refractory to other tyrosine kinase inhibitors supporting the notion that there is an absence of total cross-resistance between axitinib and other TKIs.

**Pazopanib**

Pazopanib (GW786034) is a selective multi-kinase inhibitor of VEGFR 1–3, PDGFR, and c-kit. Results of a phase II randomized discontinuation trial in 225 patients with metastatic RCC in the first and second line setting revealed a partial response in 61 patients (27%) and stable disease in 104 patients (46%). Common adverse events included diarrhea, cutaneous manifestations, and hypertension [27]. The results were recently updated at ASCO 2008, and illustrated an ORR of 34.7% (CR: 1.3%, PR: 33.3%). Stable disease was achieved in 44.5% of patients, and median PFS was 11.3 months [28].

**Cediranib**

Cediranib (AZD2171) is an orally available selective inhibitor of VEGFR 1, 2, 3, PDGFR, c-kit, and FLT-4. At ASCO 2008, a phase II trial was presented that included 43 patients with advanced untreated RCC. Partial responses were observed in 12 patients (38%) and stable disease was observed in 15 patients (47%). Overall tumor
control rate was observed in 27 patients (84%), and median PFS was 8.7 months. Treatment-related adverse events were tolerable, and included hypertension and fatigue [29].

**Mammalian target of rapamycin inhibitors**

**Temsirolimus**

Temsirolimus is a highly specific inhibitor of the mammalian target of rapamycin (mTOR), a large polypeptide kinase which forms part of the PI3K/Akt pathway. It is a central regulator of intracellular signaling pathways involved in tumor cell growth, proliferation and angiogenesis [30,31]. Its effect on advanced refractory RCC patients was demonstrated initially in a randomized phase II trial of patients with metastatic RCC. Although the ORR was only 7%, the main benefit was disease stabilization with 51% of patients achieving a response or stable disease for more than 6 months [32]. This trial led the way to its evaluation in a phase III clinical trial in patients with previously untreated intermediate or poor-risk advanced RCC [33]. The study compared the use of single agent temsirolimus, single agent IFN-α, and a combination of temsirolimus plus IFN-α in these patients. Temsirolimus monotherapy significantly prolonged the median OS compared to IFN-α as a single agent (10.9 months vs 7.3 months). Furthermore, patients receiving temsirolimus had a significantly longer PFS than patients receiving IFN-α (3.7 months vs 1.9 months). The combination group also shared a PFS of 3.7 months. It was approved for the treatment of advanced RCC in May of 2007. Toxicities from single-agent temsirolimus included fatigue (54%), nausea (37%), rash (37%) and dyspnea (30%). Temsirolimus showed a survival benefit in this group of intermediate to poor risk patients with advanced RCC, and future studies in good risk populations would be of interest.

**Everolimus**

Everolimus (RAD001) is an oral mTOR inhibitor that has gained attention in recent months. It was tested in the first- and second-line setting in 37 advanced RCC patients in a phase II clinical trial [34]. Twelve of these patients had partial responses, and 19 of them were stable for more than 3 months. A phase III randomized double-blind placebo controlled trial presented at ASCO 2008 showed significant PFS over placebo in patients with prior treatment of tyrosine kinase inhibitors including sorafenib and sunitinib [35]. Two hundred seventy two patients were randomized to everolimus and 138 patients to placebo; results showed a significant difference in PFS in patients receiving everolimus as compared to placebo (4 months vs 1.9 months). Its safety profile was favorable with the most common adverse events being stomatitis, anemia and asthenia. This study has established the role of everolimus as second or third line therapy after treatment failure of tyrosine kinase inhibitors.

Everolimus was also evaluated in combination therapy with sorafenib in a phase I study as well as with bevacizumab in a phase II study at ASCO 2008 with both trials showing anti-tumor activity and tolerability of combination therapy [36,37].

**Immunomodulators**

**Thalidomide and its analogs**

Thalidomide is a potent immunomodulatory drug with antiangiogenic properties. Initial studies showed thalidomide to have potential activity in advanced RCC [38-41]. However, a randomized phase II study of 60 patients refractory to immunotherapy did not show promising results [42]. These patients were randomized to receive either thalidomide or medroxyprogesterone. All patients receiving medroxyprogesterone experienced progression of disease, while only 3 patient in the thalidomide arm achieved stable disease at 3 months [42]. Further studies using thalidomide in combination with other agents are ongoing [43].

Lenalidomide is a thalidomide derivative with potent immunomodulatory and antiangiogenic properties. In a recent open-label single center phase II trial, 40 newly diagnosed RCC patients were treated with oral lenalidomide monotherapy [44]. A complete response was seen in one patient (3%), partial response was seen in 3 patients (8%), and stable disease was observed in 21 patients (53%). The most common adverse events were fatigue, neutropenia and thrombocytopenia. The activity in RCC has also been observed in other small phase II trials [45,46]. Further studies will be needed to assess its efficacy in advanced RCC.

**Monoclonal antibodies**

**Bevacizumab**

Bevacizumab is a humanized monoclonal antibody that inhibits tumor angiogenesis by targeting VEGF. It neutralizes all of the major isoforms of VEGF [47]. Initial evaluation began with a randomized, double-blind phase II trial comparing bevacizumab at low-dose and high-dose to placebo in 116 patients with cytokine-refractory RCC. Bevacizumab treatment led to significant prolonged time to progression of disease in the high-dose group compared to placebo (4.8 months vs 2.5 months) [48]. These results were the first to prove the concept that the VEGF signaling pathway is important for the progression of RCC in humans. It also led to evaluation of bevacizumab in combination with other therapeutic agents. The AVOREN trial was a randomized, double-blind phase III trial (n = 649) investigating the standard therapy of IFN-α plus placebo versus IFN-α plus high dose bevacizumab [49]. The
median PFS for patients was significantly prolonged in the patients in the bevacizumab arm when compared with IFN-α alone (10.2 months vs 5.4 months). In addition, the ORR was also greater in the bevacizumab arm when compared with IFN-α alone (31% vs 13%). Serious adverse events were more common in patients treated with bevacizumab plus IFN-α when compared with IFN-α alone (29% vs 16%).

Bevacizumab therapy was also evaluated in pre-surgical patients with metastatic RCC at ASCO 2008 [50]. The study was initiated to evaluate the safety and efficacy of bevacizumab therapy prior to cytoreductive nephrectomy. Of the 48 patients that were enrolled in the study, 1 patient achieved a complete response of the target lesion, 4 achieved a partial response, and 27 achieved stable disease. The ORR was 10.9%. It was concluded that bevacizumab treatment prior to nephrectomy was feasible and a safe treatment option. Bevacizumab has also been evaluated in combination with other agents including IL-2, sorafenib, sunitinib, temsirolimus, and erlotinib [51-55].

G250
G250 is a chimeric monoclonal antibody directed against carbonic anhydrase IX, a heat-sensitive surface antigen which is ubiquitously expressed in RCC [56]. In an early clinical trial accruing 35 patients with metastatic RCC, daily low dose IL-2 was combined with G250 and the result was optimistic. Three patients had partial responses and 5 patients had stable disease for at least 6 months. The median OS was 22 months [57]. Phase III randomized trials are currently underway further evaluating G250 in RCC.

Epothilones
Epothilones are a new class of cytotoxic agents derived from the fermentation of broth of the myxobacterium Sorangium cellulosum. Ixabepilone is a semisynthetic analog of epothilone B analog, a non-taxane microtubule-stabilizing agent active against cancers insensitive to paclitaxel. On October 16, 2007 it was approved for the treatment of metastatic, refractory breast cancers in combination with capcitabine. A phase II study was presented at ASCO 2008 investigating its activity in metastatic RCC [58]. Eighty seven patients with advanced RCC received ixabepilone, and results revealed an ORR of 12.6% with 1 patient achieving a complete response and 10 patients achieving partial responses. Median response duration was 5.5 months, and median OS of patients with clear cell histology was 19.25 months. Treatment related adverse events were predominantly grade I and II. It is the first time that a cytotoxic chemotherapeutic agent showed significant efficacy in RCC. This agent may be combined with other novel agents in the future.

Summary
With multiple therapeutic options available for advanced RCC, the optimal treatment is unclear. Based on current evidence, the following approaches may be followed, as summarized in Table 1. In the first line setting, high-dose IL-2 may be used for patients with good prognostic features and clear cell histology; it is the only therapy which may provide a benefit of long-term complete response. Temsirolimus should be the standard therapy for patients with poor prognostic features because of survival advantage. Sunitinib should be the drug of choice in patients with good-intermediate prognostic features, as the updated data from 2008 ASCO has shown that it improves survival. Bevacizumab in combination with interferon α has been shown to increase progression-free survival, and may be considered in patients who do not tolerate sunitinib. In the second line setting, sorafenib and everolimus may be used in patients with prior cytokine therapy and prior TKI treatment respectively due to progression-free survival benefit. The use of other agents should be in the setting of clinical trials.

Prostate cancer
Prostate cancer is the most common non-cutaneous malignancy in men. For advanced disease, eventually almost all of patients will develop resistance to androgen deprivation therapy based on medical or surgical castration. Historically, patients with castration-refractory prostate cancer (CRPC) had a median survival of approximately 12 months with scant treatment options [59]. Chemotherapy was previously considered to have an insignificant role in CRPC; however in 2004, two pivotal phase III trials (SWOG 9916 and TAX 327) led to the approval of docetaxel in combination with prednisone as the standard treatment of CRPC, and opened the door to a new era of prostate cancer treatment [60,61]. Since the approval of docetaxel, treatment approaches to CRPC centered around two tactics: the first was to utilize docetaxel as a starting place for combination therapy. The second was to take advantage of novel therapeutic agents. Here we will mainly focus on novel agents with activity for CRPC. Below we have reviewed recent clinical trials on the use of novel agents in the treatment of CRPC (efficacy data summarized in Table 2).

Satraplatin
Satraplatin is an oral third generation platinum compound with activity against a variety of solid tumors. It has preclinical antitumor activity comparable with that of cisplatin but a better toxicity profile. In a randomized phase III trial led by European Organization for Cancer Research (EORTC) with a target sample size of 380 patients of CRPC, the trial was closed to further accrual by the sponsoring company after 50 randomized patients. An ad hoc analysis demonstrated a significant median PFS advantage.
of satraplatin over prednisone itself (5.2 months vs 2.5 months) as well as a significant improvement in PSA response (33% vs 9%) [62].

This data led to the evaluation of satraplatin plus prednisone in a multi-national placebo-controlled phase III trial known as the SPARC (Satraplatin and Prednisone Against Refractory Cancer) which pitted satraplatin plus prednisone against placebo plus prednisone as second-line therapy in patients with CRPC [63]. Initial results appeared promising with a PFS in favor of satraplatin (11.1 weeks vs 9.7 weeks), but updated results at ASCO 2008 were disappointing. Despite the fact that there was significant improvement in the satraplatin group in PFS, time to progression, PSA response, objective tumor response, pain response, and duration of pain response, there was no improvement in OS (61.3 weeks vs 61.4 weeks) [64]. Nevertheless, favorable trends were observed in the subgroup of patients that had received prior docetaxel therapy. The most common toxicities included myelosuppression and thrombocytopenia. It was concluded that satraplatin was a tolerable treatment which improved PFS, but studies are underway attempting to pinpoint a subgroup of patients who may benefit from this treatment.

**Angiogenesis Inhibitors**

Angiogenesis is an important and tightly regulated factor in the development of tumor growth and metastasis [65]. Several angiogenesis inhibitors have been undergoing evaluation in CRPC, including bevacizumab, thalidomide, sorafenib, sunitinib, and cediranib (AZD2171).

The efficacy of bevacizumab as a single agent in CRPC is marginal [66]. However, significant activity was observed when it was combined with docetaxel and estramustine in the Cancer and Leukemia Group B (CALGB) 9006 trial [67]. The results showed a 50% or greater PSA decline in 81% of 79 chemotherapy naïve patients with a median time to progression of 9.7 months and median OS of 21 months. This led to the initiation of the ongoing CALGB 90401 phase III trial treating CRPC patients with docetaxel and prednisone with or without bevacizumab.

Thalidomide has also been of interest in CRPC because of its anti-angiogenic and immunomodulatory properties. In a randomized phase II trial, 63 patients with CRPC were treated with either a low-dose or a high-dose of thalidomide [68]. Of 50 patients in the low dose arm, 9 (18%) had a ≥50% decrease in PSA which was maintained at least 28 days. There were 4 patients who maintained this decrease in PSA for at least 150 days. These results led the investigators to perform a randomized phase II trial including 75 chemotherapy naïve CRPC patients treated with either docetaxel or docetaxel plus thalidomide [69]. Patients were randomized in a 1:2 fashion with 25 patients receiving docetaxel alone and 50 patients receiving the combination. Of 24 patients receiving docetaxel alone, 37% had a PSA decrease >50% while of 47 patients in the combination arm 53% had a PSA decrease of >50%. The 18-month survival was 68% for the 2 groups, with a median progression-free survival of 3.7 months in the single agent arm versus 5.9 months in the combination arm; OS was 14.7 months versus 28.9 months. Although the combination was tolerated well, increased thromboembolic events were observed in the combination arm.

These studies involving angiogenesis inhibitors prompted evaluation of both agents together in combination with docetaxel. At ASCO 2008, a single arm phase II trial using thalidomide, docetaxel and bevacizumab was presented [70]. Sixty patients with chemotherapy naïve CRPC were treated with the combination of docetaxel, thalidomide and bevacizumab with the addition of enoxaparin for thrombosis prevention as well as pegfilgrastim support.

### Table 2: Efficacy of novel agents in CRPC.

| Mechanism                  | Agent                  | PSA Response Rate |
|----------------------------|------------------------|-------------------|
| **Cytotoxic**              | Satraplatin            | 33% 1st line [62] |
|                            | Patupilone             | 25% 2nd line [64] |
|                            | Ixabepilone            | 42% 2nd line [80] |
|                            | Sagopilone             | 17–20% 2nd line [77] |
| **Immunomodulation**       | Thalidomide            | 29% 1st line [81] |
|                            | Abiraterone Acetate    | 60% 1st line [83] |
|                            |                        | 40% 2nd line [84] |
| **Androgen synthesis inhibition** | Bevacizumab/Thalidomide/Docetaxel | 53% 1st line [69] |
|                            | Bevacizumab/Docetaxel/Estramustine | 88% 1st line [70] |
|                            | Bevacizumab/Docetaxel | 81% 1st line [67] |

**Abbreviations:** CRPC, castration-refractory prostate cancer; VEGFR, vascular endothelial growth factor receptor.
for neutropenia. 88% of patients had a PSA decline of 50%, and 71% of patients had a PSA decline of 80%. The ORR was 63%, and the median PFS was estimated to be 18.2 months. Toxicities included febrile neutropenia, osteonecrosis of jaw, syncope, GI perforation and thrombosis. These results showed a promising durable control of the disease with the regimen, and future studies may need to explore a combination of angiogenesis inhibitors with a better toxicity profile.

Several TKIs including sorafenib, sunitinib, and cediranib have also been evaluated in phase II studies showing promising activity in CRPC with and without prior docetaxel treatment [71-75]. Interestingly, PSA does not appear to be a good predictor for disease progression in patients treated with sorafenib, suggesting that clinical and radiographic evidence may be a better marker to assess the activity of these new agents.

**Epothilones**
With docetaxel’s success in CRPC, the use of epothilones became attractive as this class of agents carries a mechanism of action similar to the taxanes. Of the epothilones, ixabepilone gained attention in the treatment of CRPC after a phase II SWOG trial of 42 chemotherapy naïve CRPC patients who received ixabepilone in the first line setting. Fourteen of the evaluable patients (33%) had a confirmed PSA response. The estimated PFS was 6 months, and the median survival was 18 months [76]. The most common toxicities were neuropathy and myelosuppression. This led to a multi-center, non-comparative, double crossover phase II study which evaluated the safety and activity of ixabepilone in patients with CRPC refractory to docetaxel-based therapy [77]. Patients were randomized to either ixabepilone alone or mitoxantrone plus prednisone, and patients who progressed while on treatment or discontinued treatment for toxicity were allowed to crossover to the other study arm. The median survival was similar in the ixabepilone and mitoxantrone arms (13 months vs 12.5 months). The PSA response for the ixabepilone group was 17% while the PSA response in the mitoxantrone group was 20%. These findings showed that these two agents had only marginal activity in the docetaxel-refractory CRPC setting. At ASCO 2008, a combination of these two agents was evaluated in a phase I study of ixabepilone, mitoxantrone and prednisone in patients with metastatic CRPC refractory to docetaxel-based therapy [78]. Thirty two patients were treated at 6 distinct dosing levels. Eight patients developed a PSA response, however 20 patients suffered high grade neutropenia. The results suggest that the combination of ixabepilone with mitoxantrone plus prednisone is feasible but may require pegfilgrastim support in the future.

A second study presented at ASCO 2008 updated results of E3803, a phase II study of ixabepilone administered on a weekly dosing schedule as opposed to every 3 weeks [79]. Patients with metastatic CRPC (n = 96) that were chemotherapy-naïve or pretreated with taxane-based therapy were treated with ixabepilone on a weekly basis. PSA response was achieved in 32% of chemotherapy-naïve and 22% of pretreated patients. This study showed that ixabepilone administered on a weekly basis was feasible.

Patupilone is another epothilone with broad spectrum pre-clinical activity in taxane-resistant models. In a phase II study in patients with CRPC refractory to docetaxel presented at ASCO 2008, 33 patients received patupilone every 3 weeks and at the time of the presentation 63% of patients achieved a PSA decline of 30% while 42% of patients achieved a PSA decline of 50%. A confirmed PSA response was seen in 26% of patients [80]. These results are encouraging as the study continues to accrue.

Sagopilone (ZK-EPO) is a fully synthetic epothilone B analogue. It was evaluated in a phase II study (n = 29) in chemotherapy-naïve CRPC patients in combination with prednisone. It showed that 21% of patients had a PSA response of 50%, and 58% of patients had a PSA response of 30% [81]. High-grade toxicities included neuropathy, fatigue, diarrhea and dizziness.

**Cilengitide**
Cilengitide (EMD 1219749) is a potent selective αvβ3 and αVβ5 integrin antagonist. Integrins are cell surface receptors that mediate a variety of cell activities including endothelial cell proliferation and migration. αvβ3 is important in bone metabolism, and may play a role in CRPC growth in bone. At ASCO 2008, a phase II randomized trial was presented in which 44 asymptomatic chemotherapy-naïve patients with metastatic CRPC were randomized to high-dose and low-dose cilengitide [82]. The primary endpoint was 6-month objective progression rate excluding PSA. There were stable disease in 27% of patients in the low dose arm and 36% of patients in the high dose arm. Cilengitide was well tolerated and had a favorable safety profile. The improvement in objective progression rate with the high-dose arm was marginal and therefore was not pursued any further. Neither dose succeeded in decreasing the 6 month objective progression rate.

**Abiraterone acetate**
One of the most exciting findings in the field of prostate cancer is the recognition that persistent androgen signaling remains critical in CRPC. Approaches to targeting androgen signaling including androgen synthesis and receptor blockade have drawn renewed interest. Abiraterone acetate (AA), a selective inhibitor of 17-α hydroxylase
and C17, 20-Lyase which is a dual enzyme responsible for adrenal androgen synthesis, has shown a promising therapeutic significance to intervene this pathway. The mechanism of action for abiraterone may be similar to ketoconazole, which inhibits multiple adrenal CYP enzymes including CYP17, and is used as second line hormonal treatment for CRPC. At 2008 ASCO, a study of AA was presented in patients who failed androgen deprivation therapy [83]. These patients were enrolled in two parallel trials; the first was a phase I/II study in chemotherapy-naive CRPC patients and the second was a phase II study in CRPC patients refractory to taxane therapy. A PSA response of >50% was seen in 60% of the patients in the chemotherapy-naive arm and in 40% of the pretreated arm. The median time to PSA progression was 252 days in the chemotherapy-naive arm and 167 days in the pretreated arm. An ultrasensitive serum testosterone assay was used to confirm significant testosterone suppression beyond conventional androgen deprivation therapy. Toxicities stemmed from mineral corticoid excess such as hypertension, hypokalemia and fluid retention but were tolerable. A second study was a combination of AA with prednisone in patients with CRPC after failure of docetaxel based chemotherapy [84]. Forty three patients were given AA with prednisone, and at 3 months 14 of 35 evaluable patients (40%) achieved a decline in PSA >50%. A third study presented at ASCO 2008 confirmed its activity in patients with ketoconazole-refractory disease, suggesting no cross-resistance between the two agents [85].

**Bladder cancer**

Despite advances in the treatment of superficial bladder cancer, many patients eventually perish from metastatic disease. It is the fourth most common cancer afflicting men and the ninth most common cancer afflicting women [1]. First-line therapy for metastatic bladder cancer has been cisplatin-based therapy for the past 20 years. In recent years, the combination of methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) has been the standard of care for the treatment of metastatic bladder cancer, but the regimen’s unfavorable toxicity has prompted a search for an alternative treatment. A recent large randomized phase III trial comparing M-VAC with the combination of cisplatin and gemcitabine (CG) offered a viable alternative [86]. The study showed no statistical difference in OS or ORR, but a more favorable toxicity profile for the CG group thus replacing M-VAC as the standard of care for patients with advanced bladder cancer. Despite these findings, treatment with these regimens rarely provides a prolonged relapse free or overall survival which has stimulated a search for more efficacious treatment including cytotoxic and targeted agents.

**Pemetrexed**

Pemetrexed is an anti-folate anti-metabolite with multiple enzyme targets involved in both pyrimidine and purine synthesis. Its efficacy in bladder cancer has been evaluated in a phase II study in the second-line setting for the treatment of advanced bladder cancer [87]. The study demonstrated an ORR of 28% and an OS of 9.6 months. In addition, it has also been evaluated in combination with gemcitabine in a phase II study of 63 patients with advanced bladder cancer in the first line setting [88]. The ORR of this combination was 26.5%, but toxicities were significant. The results were disappointing in that the ORR and OS appear inferior to standard cisplatin-based regimens.

**Vinflunine**

Vinflunine is a novel vinca alkaloid that inhibits tubulin and acts to inhibit assembly of microtubules. It has recently gained attention in the treatment of advanced bladder cancer after phase I studies confirmed anti-tumor activity. In a phase II study treating 51 patients who had failed first-line cisplatin containing regimens, vinflunine resulted in an ORR of 18%, a PFS of 3 months and a median OS of 6.6 months [89]. This study led to the initiation of a phase III trial of vinflunine plus best supportive care (BSC) versus BSC alone as second-line therapy after failure of a cisplatin-containing regimen in transitional cell carcinoma of the urothelium (TCCU) presented at ASCO 2008 [90]. Three hundred seventy patients were randomized in a 2:1 fashion to vinflunine plus BSC vs BSC, and the results showed that patients included in the vinflunine group achieved a median 2 month overall survival advantage (6.9 months vs 4.6 months) but was not statistically significant (p = 0.29). However, the planned multivariate analysis adjusting for prognostic factors showed improved survival with vinflunine (HR = 0.77, p = 0.036). These results may support the role of vinflunine as a standard second line treatment for advanced TCCU.

**Traztuzumab**

Trastuzumab is a humanized monoclonal antibody against Her-2/neu approved for the treatment of Her-2/neu positive breast cancer patients. In a phase II study evaluating trastuzumab’s activity in advanced Her-2/neu positive bladder cancer, 44 patients with Her-2/neu positive bladder cancer were treated with a combination of paclitaxel, carboplatin, gemcitabine and trastuzumab [91]. The results demonstrated an ORR of 70% with a median time to progression of 9.3 months and an OS of 14.1 months, with 23% of patients experienced cardiotoxicity. Lapatinib, an inhibitor of HER-2/neu tyrosine kinase, has also been evaluated in a phase II trial, and it showed ORR in 14% of patients and a median time to progression equivalent to other second line therapies (8.6...
weeks) [92]. These results warrant further study of targeting Her-2 signalling pathway.

**TKI**

The efficacy of TKIs in advanced bladder cancer has been explored by some studies presented at ASCO 2008. Sunitinib's activity in relapsed or refractory bladder cancer was evaluated by a phase II study [93]. In this study, 45 patients who received ≤4 previous chemotherapy regimens were treated with sunitinib as a single-agent. Results showed that 3 patients achieved a partial response and 11 patients achieved stable disease. Radiographic regression was observed in liver, lung, bone, bladder, soft tissue and lymph node lesions. This trial demonstrated that sunitinib does have activity in bladder cancer. Sorafenib was also evaluated at in a phase II trial (E1804) where 27 patients were accrued for treatment [94]. The first stage of accrual was suspended for a pre-planned efficacy evaluation where criteria for continuing on to the second stage of accrual were not met. For evaluable patients, no objective responses were observed and median OS was 6.8 months. It seems that sorafenib as a single agent had minimal activity in bladder cancer.

**Testicular cancer**

Testicular cancer is the most common cancer diagnosis in males between the age of 15 and 35 years [1]. The majority of testicular tumors are germ cell tumors (GCT). The cure rate is the highest of any solid organ tumor and stems from the utilization of highly effective chemotherapy.

The treatment for early stage GCT has been controversial for both seminoma and non-seminomatous tumors. Treatment options after resection of a stage I seminoma include active surveillance, radiation to the paraaortic lymph nodes, or single agent carboplatin. At the recent ASCO 2008, an updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214) compared one course of carboplatin at AUC 7 with adjuvant radiation for stage I seminoma [95]. As relapses may occur 10 years following treatment, patients were continued to be followed for data collection. Patients (n = 1,447) were randomized in a 3:5 ratio (carboplatin:radiation). The relapse free rate (RFR) at five years was 95% for the carboplatin group and 96% for the radiation group. Only one death from seminoma was reported. However, there was an increased risk of developing a second GCT in the radiation arm as compared to the carboplatin arm (2 patients versus 15 patients). It was concluded that a single dose of carboplatin was not inferior to radiation therapy in stage I seminoma, and carboplatin therapy was associated with a significantly decreased risk of developing a second GCT.

For advanced GCT, the interest has been to find the best salvage treatment. There are mainly two approaches used in the second line setting; combination chemotherapy based on ifosfamide and cisplatin or high-dose chemotherapy (HDCT) with stem cell rescue. HDCT has been used successfully in GCT since the early 1980's, but its use has traditionally been limited by treatment-related toxicities and mortality. There is limited data comparing conventional chemotherapy and HDCT in the salvage setting. A retrospective match-pair analysis found HDCT to be more beneficial [96]. From two large databases, 193 patients with relapsed or refractory non-seminomatous GCT were identified. In 74 of those patients, salvage treatment by HDCT was to be administered. Patients were matched based on primary tumor location, response to first-line treatment, duration of this response and serum levels of the tumor. The analysis suggested a benefit from HDCT, with an estimated absolute improvement in event-free survival of between 6 and 12% and in overall survival of between 9 and 11% at 2 years. However, this conclusion is not supported by a phase III study. The trial (n = 280) was performed to compare conventional salvage chemotherapy to HDCT [97]. Patients were randomly assigned to receive either four cycles of cisplatin, ifosfamide and etoposide (or vinblastine) or three such cycles followed by high-dose carboplatin, etoposide and cyclophosphamide with stem cell support. Complete and partial response rates were similar in both treatment arms (56%). There was 3% treatment related deaths in the conventional arm and 7% treatment related deaths in the HDCT. There was no significant difference in 3 year event free survival or OS.

The German Testicular Cancer Study Group attempted a prospective study in the salvage setting comparing one cycle of conventional chemotherapy consisting of etoposide, ifosfamide and cisplatin (VIP) followed by one cycle of HDCT versus 3 cycles of VIP followed by one cycle of HDCT [98]. The study was stopped prematurely as a result of excess mortality deaths in the second arm, but the investigators found no difference in the survival probabilities between the two groups. With limited data comparing conventional chemotherapy with HDCT, this topic will remain controversial, and further studies will be needed to identify a selected group of patients who may benefit from HDCT.

**Conclusion**

The treatment of advanced renal cell cancers has evolved dramatically with the use of new targeted agents including bevacizumab, sunitinib, sorafenib, temsirolimus, and everolimus. The challenge will be how to sequence or combine these new agents for optimal results. Better understanding of prostate biology has led to the development of new hormonal drugs and a variety of cytotoxic and targeted agents. With additional novel agents and
combinations under evaluation, the future of GU oncology appears promising and exciting.

**List of abbreviations used**

ASCO: American society of clinical oncology; CALGB: Cancer and Leukemia Group B; EORTC: European Organization for Cancer Research; RCC: renal cell carcinoma; CRPC: Castration-refractory prostate cancer; GCT: Germ cell tumors; IL-2: Interleukin-2; IFN-α: Interferon-α; HDCT: High-dose chemotherapy; VIP: etoposide, ifosfamide and cisplatin; VH: Von-Hippel-Lindau; VEGF: Vascular endothelial growth factor; EGF: Epidermal growth factor receptor; PDGF: Platelet-derived growth factor; PI3K: Phosphatidylinositol 3-kinase; mTOR: mammalian target of rapamycin; TKI: Tyrosine Kinase Inhibitors; VEGFR: Vascular endothelial growth factor receptor; PDGFR: Platelet-derived growth factor receptor family; c-KIT: stem-cell growth factor receptor; Flt-3: Fms-like tyrosine kinase 3; RET: the receptor encoded by the ret proto-oncogene; KIT: stem-cell growth factor receptor; Flt-3: Fms-like tyrosine kinase 3; VHL: Von-Hippel-Lindau; VEGF: Vascular endothelial growth factor; PDGF: Platelet-derived growth factor; PI3K: Phosphatidylinositol 3-kinase; mTOR: mammalian target of rapamycin; KIT: stem-cell growth factor receptor; Flt-3: Fms-like tyrosine kinase 3; VHL: Von-Hippel-Lindau; VEGF: Vascular endothelial growth factor; PDGF: Platelet-derived growth factor; PI3K: Phosphatidylinositol 3-kinase; mTOR: mammalian target of rapamycin; KIT: stem-cell growth factor receptor; Flt-3: Fms-like tyrosine kinase 3; VHL: Von-Hippel-Lindau; VEGF: Vascular endothelial growth factor.

**Competing interests**

SW is a speaker for Pfizer Inc., and has received honoraria from Onyx Pharmaceuticals.

**Authors’ contributions**

DC and SW participated in the conception, drafting, and revision for the study. All authors read and approved the final manuscript.

**Acknowledgements**

SW is supported by the Research Foundation of SUNY.

**References**

1. NCI: Surveillance Epidemiology and End Results. www.seer.cancer.gov 2008.

2. Patel P CR Motzer R: Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006, 94:614.

3. Pantuck A ZA Belfdegrun A: The changing natural history of renal cell carcinoma. J Urol 2001, 166:1611.

4. Cohen H MGF: Spontaneous regression of metastatic renal cell carcinoma. New England Journal of Medicine 2003, 353(23):2477-2490.

5. Snow R SP: medical progress: renal-cell carcinoma. The Journal of urology 2005, 173(2):522-528.

6. Motzer R BN Nanus D: Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 2004, 10(18 Pt 2):6282s-6295s.

7. Wilhelm S CD: BAY 43-9006: preclinical Data. Current Pharm Des 2002, 8:2255.

8. Ratain M ET Stadler W et al: Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology 2006, 24:2505.

9. Escudier B ET Stadler W et al: Sorafenib in advanced clear-cell renal-cell carcinoma. New England Journal of Medicine 2007, 356:125.

10. Bukowski R ET Szczylzik C, et al: Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. (Abstract). Journal of Clinical Oncology 2007, 25:2404.

11. Szczylzik C DT Staehler M, Rolland F et al: Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. Journal of Clinical Oncology 2007 ASCO annual meeting 2007, Chicago, Illinois (Abstract #5025):240s.

12. Shepard D RB Garcia J, Hutson P et al: A multicenter prospective trial of sorafenib in patients with metastatic clear cell renal cell carcinoma refractory to prior sunitinib or bevacizumab. Journal of Clinical Oncology 2008 ASCO annual meeting 2008, Chicago, Illinois (Abstract #1523):280s.

13. Chu D LME Fillos T, Wu S: Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008, 47(2):176-186.

14. Hendel DL LA Xin X et al: In vivo antitumor activity of SU 11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clinical Cancer Research 2003, 9:327-337.

15. Gordon M MD Guirguis R et al: ABT-510, an anti-angiogenic thrombospondin-1 mimetic peptide exhibits favorable safety profile and early signals of activity in a randomized phase I trial. Proc Am Soc Clin Oncology 2003, 22(abstrat #780).

16. Motzer R MM Redman B et al: Activity of SU 11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2006, 24:16-24.

17. Motzer R RB Bukowski R et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295:2516-2524.

18. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylzik C, Kim ST, Chen I, Bycott PW, Bauml CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England journal of medicine 2007, 356(2):115-124.

19. Figlin R HT Tomczak M et al: Overall survival with sunitinib versus interfero alfa as first line treatment of metastatic renal cell carcinoma. Journal of Clinical Oncology 2008 ASCO annual meeting 2008, Chicago, Illinois (abstract #5024):256s.

20. O’Brien M RP Motzer R: Sunitinib therapy in renal cell carcinoma. BJU international 2008, 101:1339-1342.

21. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liu KF, Freddo J, Trask PC, Kim S, Rini BI: Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. The lancet oncology 2007, 8(11):975-984.

22. Rini B WG Hudes G, Stadler W et al: Axitinib in patients with metastatic renal cell cancer refractory to sunitinib. Journal of Clinical Oncology 2007, 25(abstrast #5032):.

23. Dutcher J WG Hudes G, Stadler W et al: Sequential axitinib therapy of patients with metastatic clear cell renal cell cancer refractory to sunitinib and sunitinib, cytokines and sorafenib, or sorafenib alone. Journal of Clinical Oncology Annual ASCO meeting 2008 2008 2008, Chicago, Illinois (abstract #5127):281s.

24. Hutson T D Machiels J de Souza P et al: Pazopanib (GW786034) is active in metastatic renal cell carcinoma: interim results of a phase II randomized discontinuation trial. Journal of Clinical Oncology ASCO meeting 2007 2007, Chicago, Illinois(25abstract #5031).

25. Hutson T DD Machiels J, de Souza P et al: Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. Journal of Clinical Oncology 2008 annual ASCO meeting 2008, Chicago, Illinois (abstract #5046):261s.

26. Siddhar S MM Hotte S, Mukherjee C et al: Activity of cediranib (AZD2171) in patients with previously untreated metastatic renal cell cancer. A phase II trial of the PPH Consortium.
33. Hudes G, CM Tomczak P et al: MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiology 1999, 178:235-246.

34. Schmelzle T, HM: TOR, a central controller of cell growth. Cell 2000, 103:253-262.

35. Atkins MM Stadler W et al: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Journal of Clinical Oncology 2004, 22:909-918.

36. Hudes G, CM Tomczak P et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine 2007, 356:2271.

37. Jac G, S Khan M, Willis J et al: A phase II trial of RAD001 in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2005, 23(abstract #5107).

38. Motzer R, EB Oudard S, Porta C et al: RAD001 versus placebo in patients with metastatic renal cell carcinoma after progression on VEGFR-TKI therapy: Results from a randomized, double-blind multicenter phase III study. Journal of Clinical Oncology 2008 ASCO annual meeting 2008, Chicago, Illinois (LABS026):1009a.

39. Rosenberg J, WV Claro R, C Ryan C et al: Phase I study of sorafenib and RAD001 for metastatic renal cell cancer: Final results of a phase II study. Journal of Clinical Oncology 2008 ASCO annual meeting 2008, Chicago, Illinois (Abstract #5109):276s.

40. Whorf R, HD Spigel D et al: Phase II study of bevacizumab and everolimus in the treatment of advanced renal cell carcinoma. Journal of Clinical Oncology 2008 ASCO annual meeting 2008, Chicago, Illinois (Abstract #5510):532s.

41. Daliani DD, Papadreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R: A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 2002, 95(4):758-765.

42. Escudier B, Lassau N, Couanet D, Angevin E, Mesratzi F, Lebogern S, Garofano A, Leboulanger C, Dupouy N, Laplanche A: Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 2002, 13(7):1029-1035.

43. Lee CP, Patel PM, Selby P, Hancock BW, Mak I, Pyle L, James MG, Beirne DA, Steeds A, H’Aern R, Gore ME, Eisen T: Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24(6):898-903.

44. Amato RJ, Malya R, Rawat A: Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. American journal of clinical oncology 2008, 31(3):237-243.

45. Amato R, HMCJ Saxena S, Khan M: Lenalidomide Therapy for Metastatic Renal Cell Carcinoma. American journal of clinical oncology 2008, 31(3):244-249.

46. Choueiri TK, Dreicer R, Rini BI, Elson P, Garcia A, Thakkar SG, Baz RH, Melhem A, translated by HA, Bukowski RM: Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 2006, 107(11):2609-2616.

47. Patel PH, Kondagunta GV, Schwartz L, Ishill N, Back J, DeLuca J, Russo F, Motzer RJ: Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Investigational new drugs 2008, 26(3):273-276.

48. Presta L, CH O’Connor S, Chisolm H et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Research 1997, 57(20):4593-4599.

49. Benci B, Puzasrka A, Koralewski P, Ravaud A, Bracarda S, Szczyluk C, Chevreau C, Filipek M, Melichar B, Bajretta G, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007, 369(9505):2103-2111.

50. Jonasch E, WC Matin S, Tamboli P et al: Presurgical bevacizumab in patients with metastatic clear cell renal cell carcinoma: A phase II study. Journal of Clinical Oncology Annual ASCO meeting 2008 2008, Chicago Illinois (abstract #5104):275s.

51. Garcia J, RB Mekhail T, Triozzi P et al: A Phase II trial of low dose interleukin-2 and bevacizumab in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology Annual ASCO meeting 2007 2007, Chicago, Illinois (abstract #15586):18s.

52. Cooney MG, DJ Dreicer R, Beatty K et al: A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors. Journal of Clinical Oncology Annual ASCO meeting 2007 2007, Chicago, Illinois (abstract #5010):18s.

53. Merchan J, LG Fitch T, Picus J et al: Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. Journal of Clinical Oncology Annual ASCO meeting 2007 2007, Chicago Illinois (abstract #5034):18s.

54. Bukowski RM, Kabbannat PF, Figlin RA, Plaherty K, Srivinas S, Vai-shampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA, McDermott D: Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007, 25(31):7889-7896.

55. Hainsworth JD, Somson JA, Spigel DR, Edwards DL, Baughman C, Greco A: Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005, 23(31):7889-7896.

56. Uemura H, NY Yoshih K, Saga S et al: MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Journal of Cancer 1999, 81(4):741-746.

57. Bleumer I, OE Oosterwijk-Wakkala J et al: A Clinical Trial with Chimeric monoclonal Antibody WXG-250 and Low Dose Interleukin-2 Pulsing Scheme for Advanced Renal Cell Carcinoma. Journal of Urology 2006, 175:57.

58. Huang M, MM Edgerly H, Koz M et al: Ixabepilone (BMS-247550) and metastatic renal cell carcinoma. Journal of Clinical Oncology Annual ASCO meeting 2008 2008, Chicago, Illinois (abstract #5053):262s.

59. Page 11 of 13

60. Mike S, HC Coles B et al: Chemotherapy for hormone refractory prostate cancer. Cachane Database Syst Rev 2006, 4(CD005247).

61. Tamonjac I, WR, Berry W et al: Docetaxel plus prednison or mitoxantrone plus prednison for advanced prostate cancer. New England Journal of Medicine 2004, 351(15):1502-1512.

62. Petryla D, TC Hussain M et al: Docetaxel and estramustine compared with mitoxantrone and prednison for advanced refractory prostate cancer. New England Journal of Medicine 2004, 351(15):1513-1520.

63. Stenberg C, WP Hechertong J et al 2005 Phase III trial of satraplatin, an oral platinum plus prednison vs. prednison alone in patients with hormone-refractory prostate cancer. Oncology 68 2-3: Phase III trial of satraplatin, an oral platinum plus prednison vs. prednison alone in patients with hormone-refractory prostate cancer. Oncology 2005, 58(1):2-9.

64. Stenberg C, PD Wijites F et al: Satraplatin demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial. Journal of Clinical Oncology 2007, 25:5019.

65. Sartor A, PD Wijtes J, Berry W et al: Satraplatin in patients with advanced hormone-refractory prostate cancer: Overall survival results from teh phase III satraplatin and prednison against refractory cancer (SPARC) trial. Journal of Clinical Oncology Annual ASCO meeting 2008 2008, Chicago, Illinois (abstract #5003):250s.

66. Bergers G LBL: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.

67. Reese D, HK Corry M et al: A Phase II trial of humanized anti-vascular endothelial growth factor antibody for the treat-ment of androgen-independent prostate cancer. Prostate Journal 2001, 3:65-70.
67. Picus J HS Rini B et al: The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: interim results of CALGB 90006. Proc Am Soc Clin Oncology 2003, 22:1578.

68. Figg WD Duray P et al: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001, 7:1888-1911.

69. Dahut W GJAP. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. Journal of Clinical Oncology annual ASCO meeting 2008, Chicago, Illinois(abstract #5000):250s.

70. Ling A RJ Weinberg V: Phase II trial of thalidomide, bev-docetaxel-based therapy. Journal of Clinical Oncology 2004, 22:2532-2539.

71. Nging Y AP Gulley J Stein et al: Phase II trial of thalidomide, bev-docetaxel-based therapy. Journal of Clinical Oncology annual ASCO meeting 2008, Chicago, Illinois(abstract #5000):250s.

72. Harzstark A Weinberg V, Sharib J, Smith D et al: Second line combination chemotherapy: A phase I study of ixabepilone, mitoxantrone and prednisone in patients with metastatic hormone-refractory prostate cancer refractory to docetaxel-based therapy. Journal of Clinical Oncology Annual ASCO meeting 2008 2008, Chicago, Illinois (abstract #5151):287s.

73. Wilding G CY Dipalpa P, Carducci M et al: E3803: Updated results on phase II study of weekly schedule of BMS-247550 for patients with castrate refractory prostate cancer. Journal of Clinical Oncology Annual ASCO meeting 2008 2008, Chicago Illinois(abstract #5070):267s.

74. Chi K B Venner P, Figg B et al: A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer who have progressed after docetaxel. Journal of Clinical Oncology Annual ASCO meeting 2008 2008, Chicago Illinois (abstract #5166):290s.

75. Graff J SD Neerukonda L, Alonso M et al: Phase II study of sago- pionole (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgen-independent prostate cancer. Journal of Clinical Oncology Annual ASCO meeting 2008 2008, Chicago Illinois (abstract #5141):284s.

76. Bradley D MS Ryan C, Dipalpa R et al: Cilengitide in asymptomatic metastatic androgen independent prostate cancer patients: a randomized phase II trial. Journal of Clinical Oncology Annual ASCO meeting 2008 2008, Chicago Illinois(abstract #5144):285s.

77. De Bono J AG Reid A, Parker C et al: Anti-tumor activity of abiraterone acetate, a CYP17 inhibitor of androgen synthesis, in chemotherapy naïve and docetaxel pre-treated castration resistant prostate cancer. Journal of Clinical Oncology Annual ASCO meeting 2008 2008, Chicago Illinois(abstract #5005):251s.

78. Danila D RD Morris M, Slaw S et al: Abiraterone acetate and prednisone in patients with progressive metastatic castration resistant prostate cancer after failure of docetaxel-based chemotherapy. Journal of Clinical Oncology Annual ASCO meeting 2008 2008, Chicago Illinois(abstract #5019):254s.

79. Ryan C S Rosenberg J, Lin et al: Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17, 20-lyase inhibitor in castration resistant prostate cancer. Journal of Clinical Oncology Annual ASCO meeting 2008 2008 . Chicago Illinois (abstract #5001):254s.

80. Von der Maase H SL Robers J et al: Long-term survival results of a randomized trial comparing gemicitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. Journal of Clinical Oncology 2005, 23:4602-4608.

81. Graff J SD Neerukonda L, Alonso M et al: Phase II study of pemetrexed for second line treatment of transitional cell carcinoma of the urothelium. Journal of Clinical Oncology 2008, 26:3451-3457.

82. Von der Maase H LJ Gravis G et al: A phase II trial of pemetrexed plus gemcitabine as first-line treatment for locally advanced or metastatic transitional cell carcinoma. Journal of Clinical Oncology Annual ASCO meeting 2008 2008, Chicago Illinois (abstract #5128):257s.

83. Hussain M MVG Petrylak D et al: Trastuzumab, paclitaxel, carboplatin, and gemicitabine in advanced human epidermal growth factor receptor-2/neu- positive urothelial carcinoma: results of a multicenter phase II trial. Journal of Clinical Oncology annual ASCO meeting 2007, 25:2218-2224.

84. Wulffing C MJ Richel D et al: A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of locally advanced/metastatic transitional cell carcinoma of the urothelial tract. Proc Am Soc Clin Oncology 2005, 23(abstract #4594):25s.

85. Gallagher D MM Gerst S, Iasonos A et al: Final results of a phase II study of sunitinib in patients with relapsed or refractory urothelial carcinoma. Journal of Clinical Oncology Annual ASCO meeting 2008 2008, Chicago Illinois(abstract #5151):287s.

86. Dreicer R LH Stein M, DiPaola R et al: Phase II trial of sorafenib in advanced carcinoma of the urothelium (E 1804): A trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology Annual ASCO meeting 2008 2008, Chicago, Illinois (abstract #5081):270s.

87. Oliver R MG Fogarty P et al: Radiotherapy versus carboplatin for stage I seminoma: Updated analysis of the MRC/EORTC randomised trial (IRCTN27163214). Journal of Clinical Oncology Annual ASCO meeting 2008 2008, Chicago Illinois(abstract #1106s).

88. Beyer JS Gerl A, Fossa S, Siegert W: High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Annals of Oncology 2002, 13(4):599-605.

89. Picus J RG Kramar A, Wands H, V, et al: Randomized trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Annals of Oncology 2005, 16(7):1152-1159.

90. Lorch A KC Hartmann J, Metzner B et al: Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumor: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. Journal of Clinical Oncology 2007, 25(19):2778-2784.

91. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995, 13(3):688-696.
100. Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC: Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996, 14(8):2410-2411.

101. Rini B RO Bukowski R et al: AG-013736, a multi-targeted tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer. Journal of Clinical Oncology 2005, 23(abstract #4509):